April 17 (Reuters) - Mayne Pharma Group Ltd MYX.AX:
SOL-GEL AND MAYNE PHARMA ANNOUNCE THE PURCHASE OF EPSOLAY® AND TWYNEO® IN THE U.S.
SOL-GEL- TO RECEIVE $16 MILLION DURING 2025
SOL-GEL- SGT-610 PHASE III TRIAL TOP-LINE RESULTS EXPECTED Q4 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.